Evidence map›Paper›PMID 30690103›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

Functional assessment of peptide-modified PLGA nanoparticles against oral biofilms in a murine model of periodontitis.

Mohamed Y Mahmoud, Jill M Steinbach-Rankins, Donald R Demuth

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Beyond antibiotics: advances in photothermal strategies for oral infections.Frontiers in bioengineering and biotechnology · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Treatment of periodontal disease: does drug delivery matter?Frontiers in bioengineering and biotechnology · 2024
    Article
  17. Review
  18. Article
  19. Overview of Antimicrobial Biodegradable Polyester-Based Formulations.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Mohamed Y MahmoudDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, United States; Center for Predictive Medicine, University of Louisville, 505 S. Hancock St., Louisville, KY 40202, United States; Department of Toxicology, Forensic Medicine and Veterinary Regulations, Faculty of Veterinary Medicine, Cairo University, Egypt. Electronic address: myabde01@louisville.edu.
Jill M Steinbach-RankinsDepartment of Bioengineering, University of Louisville Speed School of Engineering, United States; Department of Microbiology and Immunology, University of Louisville School of Medicine, United States; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, United States; Center for Predictive Medicine, University of Louisville, 505 S. Hancock St., Louisville, KY 40202, United States. Electronic address: jmstei01@louisville.edu.
Donald R DemuthDepartment of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, 501 S. Preston St., Louisville, KY 40202, United States; Department of Microbiology and Immunology, University of Louisville School of Medicine, United States. Electronic address: drdemu01@louisville.edu.
University of Louisville · USCairo University · EG

Funding

Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative IntravaginalP20GM125504 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Shirin Ghods · 2018 to 2026
$24.4M
Structure-based design and synthesis of peptidominetics targeting P. gingivalisR01DE023206 · NIDCR · UNIVERSITY OF LOUISVILLE · PI DEMUTH, DONALD R, LUZZIO, FREDERICK ANTHONY · 2013 to 2017
$1.9M
Nanoparticle delivery vehicles targeting P. gingivalisR21DE025345 · NIDCR · UNIVERSITY OF LOUISVILLE · PI DEMUTH, DONALD R, STEINBACH-RANKINS, JILL · 2016 to 2017
$424k
NIDCR NIH HHS R01 DE023206NIDCR NIH HHS R21 DE025345NIGMS NIH HHS P20 GM125504
6 · The paper itself

Abstract

The interaction of the periodontal pathogen Porphyromonas gingivalis (Pg) with commensal streptococci promotes Pg colonization of the oral cavity. Previously, we demonstrated that a peptide (BAR) derived from Streptococcus gordonii (Sg) potently inhibited adherence of Pg to streptococci and reduced Pg virulence in a mouse model of periodontitis. Thus, BAR may represent a novel therapeutic to control periodontitis by preventing Pg colonization of the oral cavity. However, while BAR inhibited the initial formation of Pg/Sg biofilms, much higher concentrations of peptide were required to disrupt an established Pg/Sg biofilm. To improve the activity of the peptide, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were surface-modified with BAR and shown to more potently disrupt Pg/Sg biofilms relative to an equimolar amount of free peptide. The goal of this work was to determine the in vivo efficacy of BAR-modified NPs (BNPs) and to assess the toxicity of BNPs against human gingival epithelial cells. In vivo efficacy of BNPs was assessed using a murine model of periodontitis by measuring alveolar bone resorption and gingival IL-17 expression as outcomes of Pg-induced inflammation. Infection of mice with Pg and Sg resulted in a significant increase in alveolar bone loss and gingival IL-17 expression over sham-infected animals. Treatment of Pg/Sg infected mice with BNPs reduced bone loss and IL-17 expression almost to the levels of sham-infected mice and to a greater extent than treatment with an equimolar amount of free BAR. The cytotoxicity of the maximum concentration of BNPs and free BAR used in in vitro and in vivo studies (1.3 and 3.4 μM), was evaluated in telomerase immortalized gingival keratinocytes (TIGKs) by measuring cell viability, cell lysis and apoptosis. BNPs were also tested for hemolytic activity against sheep erythrocytes. TIGKs treated with BNPs or free BAR demonstrated >90% viability and no significant lysis or apoptosis relative to untreated cells. In addition, neither BNPs nor free BAR exhibited hemolytic activity. In summary, BNPs were non-toxic within the evaluated concentration range of 1.3-3.4 μM and provided more efficacious protection against Pg-induced inflammation in vivo, highlighting the potential of BNPs as a biocompatible platform for translatable oral biofilm applications.

Indexed as

Alveolar Bone LossAnimalsAnti-Bacterial AgentsBacterial AdhesionBacterial ProteinsBiofilmsDisease Models, AnimalDrug LiberationEpithelial CellsGingivaHumansInterleukin-17MiceMice, Inbred BALB CMouthNanocapsulesAnti-Bacterial AgentsBacterial ProteinsInterleukin-17NanocapsulesPeptidesPolylactic Acid-Polyglycolic Acid CopolymerDrug deliveryOral biofilmPeptide deliveryPeriodontal diseasePoly(lactic-co-glycolic acid)Polymer nanoparticlePorphyromonas gingivalisStreptococcus gordonii

Identifiers

PMID30690103
PMCPMC6463477
OpenAlexW2913736889

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.